Cargando…

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have been causing increasingly serious drug resistance problem, development of broadly effective and hard-to-escape anti-SARS-CoV-2 agents is an urgent need. Here, we describe further development and characterization of two SAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Mengjia, Yao, Weitong, Li, Yujun, Ma, Danting, Zhang, Zhaoyong, Wang, Haimin, Tang, Xiaojuan, Wang, Yanqun, Li, Chao, Cheng, Dechun, Lin, Hua, Yin, Yandong, Zhao, Jincun, Zhong, Guocai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434153/ https://www.ncbi.nlm.nih.gov/pubmed/37395664 http://dx.doi.org/10.1128/spectrum.01100-23

Ejemplares similares

SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig
por: Li, Yujun, et al.
Publicado: (2020)

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
por: Zhang, Zhaoyong, et al.
Publicado: (2021)

Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice
por: Zhu, Airu, et al.
Publicado: (2021)

Engineering ACE2 decoy receptors to combat viral escapability
por: Arimori, Takao, et al.
Publicado: (2022)

A potent and broad‐spectrum neutralizing nanobody for SARS‐CoV‐2 viruses, including all major Omicron strains
por: Yao, Hebang, et al.
Publicado: (2023)

Outsmarting SARS-CoV-2 by empowering a decoy ACE2
por: Sokolowska, Milena
Publicado: (2020)

A decoy mutant ACE2 designed to reduce COVID-19
por: Maishan, Mazharul, et al.
Publicado: (2022)

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
por: Havranek, Brandon, et al.
Publicado: (2023)

Cpf1 proteins excise CRISPR RNAs from mRNA transcripts in mammalian cells
por: Zhong, Guocai, et al.
Publicado: (2017)

ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection
por: Ching, Krystal L., et al.
Publicado: (2022)

Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence
por: Mou, Huihui, et al.
Publicado: (2018)

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
por: Zhang, Haoran, et al.
Publicado: (2022)

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
por: Linsky, Thomas W., et al.
Publicado: (2020)

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
por: Tanaka, Shiho, et al.
Publicado: (2021)

Computationally engineered ACE2 decoy binds with nanomolar affinity with the SARS-CoV-2 spike protein
por: Islam, Mohammad S., et al.
Publicado: (2022)

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
por: Zhang, Lianghui, et al.
Publicado: (2022)

Machine learning guided design of high affinity ACE2 decoys for SARS-CoV-2 neutralization
por: Chan, Matthew C., et al.
Publicado: (2021)

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
por: Zhang, Lianghui, et al.
Publicado: (2022)

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
por: Chan, Kui K., et al.
Publicado: (2021)

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
por: Chan, Kui K., et al.
Publicado: (2020)

Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma
por: Zhou, Jian, et al.
Publicado: (2014)

NOX2 decoy peptides disrupt trauma-mediated neutrophil immunosuppression and protect against lethal peritonitis
por: Husain, Maroof, et al.
Publicado: (2020)

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
por: Liu, Yubin, et al.
Publicado: (2023)

Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model
por: Zhang, Zhaoyong, et al.
Publicado: (2020)

An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo
por: Ikemura, Nariko, et al.
Publicado: (2022)

Generation of enzymatically competent SARS‐CoV‐2 decoy receptor ACE2‐Fc in glycoengineered Nicotiana benthamiana
por: Castilho, Alexandra, et al.
Publicado: (2021)

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
por: Capraz, Tümay, et al.
Publicado: (2021)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants
por: Tang, Haoneng, et al.
Publicado: (2022)

Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2
por: Verstraete, Meghan M., et al.
Publicado: (2023)

High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
por: Sims, Joshua J., et al.
Publicado: (2022)

Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
por: Wang, Yifan, et al.
Publicado: (2022)

Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
por: Inal, Jameel M.
Publicado: (2020)

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
por: Du, Yanyun, et al.
Publicado: (2021)

Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS‐CoV‐2
por: Kim, Jeonghwan, et al.
Publicado: (2022)

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
por: Zhang, Lianghui, et al.
Publicado: (2022)

Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents
por: Zhou, Qing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r1tnlfq8hr71sep2067paoms3a